PSNL

14.3702.38%
MP

Michael P. Snyder

Co-Founder and Member of Clinical & Scientific Advisory Board

Dr. Michael P. Snyder, also known as Mike, PhD., is a Co-Founder and serves as Chair of the Scientific Advisory Board at RTHM, Inc. He is Member of Technical Advisory Board at Abbratech, Inc. He is Scientific Co-Founder of IOLLO, INC. Dr. Snyder is Co-Founder of Q Bio, Inc. He serves as Member of Advisory Board at Neuvivo, Inc. since 2026 and also served as Member of Scientific Advisory Board until 2026. He is the Chairman of Genetics Department at Stanford University. Dr. Snyder is the Principal Investigator of Regulome. He is an Advisor at R42 Group. He is a Co-Founder of Personalis, Inc. and serves as its Member of Clinical & Scientific Advisory Board. He is a Professor of Genetics. He is a Member of Cancer Center and Bio-X. He is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University School of Medicine under the supervision of Dr. Ronald Davis. He is a leader in the field of functional genomics and proteomics. His laboratory study was the first to perform a large-scale functional genomics project in any organism and currently carries out a variety of projects in the areas of genomics and proteomics both in yeast and humans. These include the large-scale analysis of proteins using protein microarrays and the global mapping of the binding sites of chromosomal proteins, development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor (TF) binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated (e.g. lncRNAs and TF binding sites) and a high diversity of transcription factor binding occurs both between and within species. He launched the field of personalized medicine by combining different state-of–the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of a person and his laboratory pioneered the use of wearables technologies (smart watches and continuous glucose monitoring) for precision health. He is a cofounder of many biotechnology companies, including SensOmics, Qbio, January, Protos, Oralome, Mirvie and Filtricine. His laboratory built the first proteome chip for any organism and the first high resolution tiling array for the entire human genome. Dr. Snyder received his B.A, Chemistry and Biology at the University of Rochester; his Ph.D. from the California Institute of Technology where he was advised by Dr. Norman Davidson.

Positions